BiotechTube

Docetaxel + Pembrolizumab

Phase 2Active
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Effect of Drug

Conditions

Effect of Drug

Trial Timeline

Jul 6, 2022 → Nov 30, 2025

NCT ID
NCT05252429

About Docetaxel + Pembrolizumab

Docetaxel + Pembrolizumab is a phase 2 stage product being developed by Merck for Effect of Drug. The current trial status is active. This product is registered under clinical trial identifier NCT05252429. Target conditions include Effect of Drug.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05252429Phase 2Active

Competing Products

20 competing products in Effect of Drug

See all competitors
ProductCompanyStageHype Score
ORIN1001Fosun PharmaPhase 1/2
40
GP404141 + NplateGEROPHARMPhase 3
69
Milademetan Treatment A + Milademetan Treatment B + Milademetan Treatment CDaiichi SankyoPhase 1
33
E7386EisaiPhase 1
33
Duloxetine + WarfarinEli LillyPhase 1
33
Budesonide NasalJohnson & JohnsonApproved
85
SHR-1603Jiangsu Hengrui MedicinePhase 1
33
Famitinib + Ifosfamide + CamrelizumabJiangsu Hengrui MedicinePhase 1/2
41
Apatinib+IE + IEJiangsu Hengrui MedicinePhase 2
52
AZD7986, oral solution, 1 to 50 mg/mL + Placebo, oral solutionAstraZenecaPhase 1
33
AZD6482 + Clopidogrel + ASAAstraZenecaPhase 1
33
Albuterol Sulfate + Nicardipine Hydrochloride + Dobutamine Hydrochloride + Phenylephrine Hydrochloride + Verapamil Hydrochloride + Phentolamine Mesylate + PlaceboAstraZenecaPhase 1
33
esomeprazole/ASA Fixed Dose Combination (FDC)AstraZenecaPhase 1
33
AZD6482 + PlaceboAstraZenecaPhase 1
33
MSC2156119JMerckPhase 1
33
daptomycinMerckPhase 3
77
Cyclosporine & Cellcept + Prograf & Cellcept + Low Dose CNI (Cyclosporine or FK) and Cellcept + Rapamune and CellceptRochePhase 1/2
41
EvolocumabAmgenPhase 1
32
GS-0976 + PlaceboGilead SciencesPhase 1
32
Varenicline (Champix)PfizerPhase 1
32

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85